nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP1A2—Carmustine—lymphatic system cancer	0.121	0.154	CbGbCtD
Azelastine—CYP3A5—Teniposide—lymphatic system cancer	0.11	0.139	CbGbCtD
Azelastine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0986	0.126	CbGbCtD
Azelastine—CYP2C19—Teniposide—lymphatic system cancer	0.0884	0.113	CbGbCtD
Azelastine—CYP2C9—Teniposide—lymphatic system cancer	0.0735	0.0935	CbGbCtD
Azelastine—CYP3A5—Vincristine—lymphatic system cancer	0.0528	0.0671	CbGbCtD
Azelastine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0499	0.0635	CbGbCtD
Azelastine—CYP3A4—Cytarabine—lymphatic system cancer	0.0434	0.0552	CbGbCtD
Azelastine—CYP3A4—Teniposide—lymphatic system cancer	0.0427	0.0544	CbGbCtD
Azelastine—ABCB1—Vincristine—lymphatic system cancer	0.0343	0.0437	CbGbCtD
Azelastine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0299	0.038	CbGbCtD
Azelastine—ABCB1—Methotrexate—lymphatic system cancer	0.0208	0.0265	CbGbCtD
Azelastine—CYP3A4—Vincristine—lymphatic system cancer	0.0206	0.0262	CbGbCtD
Azelastine—Viral infection—Mitoxantrone—lymphatic system cancer	0.00185	0.00863	CcSEcCtD
Azelastine—Ulcerative stomatitis—Methotrexate—lymphatic system cancer	0.0018	0.00841	CcSEcCtD
Azelastine—Ulcer—Mitoxantrone—lymphatic system cancer	0.00177	0.00824	CcSEcCtD
Azelastine—Vertigo—Mechlorethamine—lymphatic system cancer	0.0017	0.00794	CcSEcCtD
Azelastine—Furuncle—Methotrexate—lymphatic system cancer	0.0017	0.00792	CcSEcCtD
Azelastine—Bronchitis—Fludarabine—lymphatic system cancer	0.00169	0.00791	CcSEcCtD
Azelastine—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00164	0.00764	CcSEcCtD
Azelastine—Abnormal vision—Carmustine—lymphatic system cancer	0.00157	0.00731	CcSEcCtD
Azelastine—Mental disability—Carmustine—lymphatic system cancer	0.00156	0.00728	CcSEcCtD
Azelastine—Mouth ulceration—Vincristine—lymphatic system cancer	0.00155	0.00724	CcSEcCtD
Azelastine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00155	0.00721	CcSEcCtD
Azelastine—Arthritis—Bleomycin—lymphatic system cancer	0.00154	0.00718	CcSEcCtD
Azelastine—Infection—Mechlorethamine—lymphatic system cancer	0.00154	0.00717	CcSEcCtD
Azelastine—Mucosal inflammation—Methotrexate—lymphatic system cancer	0.0015	0.00702	CcSEcCtD
Azelastine—Haematuria—Fludarabine—lymphatic system cancer	0.0015	0.00699	CcSEcCtD
Azelastine—Flushing—Teniposide—lymphatic system cancer	0.00149	0.00695	CcSEcCtD
Azelastine—Epistaxis—Fludarabine—lymphatic system cancer	0.00148	0.00691	CcSEcCtD
Azelastine—Sinusitis—Fludarabine—lymphatic system cancer	0.00147	0.00688	CcSEcCtD
Azelastine—Eye pain—Carmustine—lymphatic system cancer	0.00144	0.00674	CcSEcCtD
Azelastine—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.0014	0.00655	CcSEcCtD
Azelastine—Pharyngitis—Fludarabine—lymphatic system cancer	0.0014	0.00653	CcSEcCtD
Azelastine—Visual impairment—Fludarabine—lymphatic system cancer	0.00136	0.00634	CcSEcCtD
Azelastine—Agitation—Teniposide—lymphatic system cancer	0.00128	0.00599	CcSEcCtD
Azelastine—Bronchospasm—Bleomycin—lymphatic system cancer	0.00127	0.00593	CcSEcCtD
Azelastine—Face oedema—Carmustine—lymphatic system cancer	0.00126	0.00588	CcSEcCtD
Azelastine—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00125	0.00585	CcSEcCtD
Azelastine—Hypertension—Teniposide—lymphatic system cancer	0.00121	0.00563	CcSEcCtD
Azelastine—Chest pain—Teniposide—lymphatic system cancer	0.00119	0.00555	CcSEcCtD
Azelastine—Urinary retention—Vincristine—lymphatic system cancer	0.00118	0.00553	CcSEcCtD
Azelastine—Confusional state—Teniposide—lymphatic system cancer	0.00115	0.00536	CcSEcCtD
Azelastine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00114	0.00532	CcSEcCtD
Azelastine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00114	0.00531	CcSEcCtD
Azelastine—Infection—Teniposide—lymphatic system cancer	0.00113	0.00528	CcSEcCtD
Azelastine—Agitation—Fludarabine—lymphatic system cancer	0.00113	0.00526	CcSEcCtD
Azelastine—Tachycardia—Teniposide—lymphatic system cancer	0.00111	0.00519	CcSEcCtD
Azelastine—Malaise—Fludarabine—lymphatic system cancer	0.00111	0.00517	CcSEcCtD
Azelastine—Haematuria—Bleomycin—lymphatic system cancer	0.0011	0.00512	CcSEcCtD
Azelastine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00109	0.0051	CcSEcCtD
Azelastine—Cough—Fludarabine—lymphatic system cancer	0.00107	0.005	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00107	0.00499	CcSEcCtD
Azelastine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00106	0.00494	CcSEcCtD
Azelastine—Myalgia—Fludarabine—lymphatic system cancer	0.00104	0.00488	CcSEcCtD
Azelastine—Discomfort—Fludarabine—lymphatic system cancer	0.00103	0.00482	CcSEcCtD
Azelastine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00103	0.0048	CcSEcCtD
Azelastine—Dyspnoea—Teniposide—lymphatic system cancer	0.00102	0.00474	CcSEcCtD
Azelastine—Confusional state—Fludarabine—lymphatic system cancer	0.00101	0.00471	CcSEcCtD
Azelastine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.001	0.00467	CcSEcCtD
Azelastine—Infection—Fludarabine—lymphatic system cancer	0.000995	0.00464	CcSEcCtD
Azelastine—Vomiting—Mechlorethamine—lymphatic system cancer	0.000983	0.00459	CcSEcCtD
Azelastine—Rash—Mechlorethamine—lymphatic system cancer	0.000974	0.00455	CcSEcCtD
Azelastine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000974	0.00455	CcSEcCtD
Azelastine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000973	0.00454	CcSEcCtD
Azelastine—Flushing—Bleomycin—lymphatic system cancer	0.000959	0.00448	CcSEcCtD
Azelastine—Weight increased—Mitoxantrone—lymphatic system cancer	0.000953	0.00445	CcSEcCtD
Azelastine—Feeling abnormal—Teniposide—lymphatic system cancer	0.000939	0.00438	CcSEcCtD
Azelastine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000932	0.00435	CcSEcCtD
Azelastine—Nausea—Mechlorethamine—lymphatic system cancer	0.000918	0.00429	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000912	0.00426	CcSEcCtD
Azelastine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000908	0.00424	CcSEcCtD
Azelastine—Herpes simplex—Methotrexate—lymphatic system cancer	0.000903	0.00421	CcSEcCtD
Azelastine—Glossitis—Methotrexate—lymphatic system cancer	0.000903	0.00421	CcSEcCtD
Azelastine—Abdominal pain—Teniposide—lymphatic system cancer	0.000901	0.0042	CcSEcCtD
Azelastine—Body temperature increased—Teniposide—lymphatic system cancer	0.000901	0.0042	CcSEcCtD
Azelastine—Paraesthesia—Fludarabine—lymphatic system cancer	0.000899	0.0042	CcSEcCtD
Azelastine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000897	0.00419	CcSEcCtD
Azelastine—Dyspnoea—Fludarabine—lymphatic system cancer	0.000893	0.00417	CcSEcCtD
Azelastine—Haematuria—Mitoxantrone—lymphatic system cancer	0.000891	0.00416	CcSEcCtD
Azelastine—Ulcer—Methotrexate—lymphatic system cancer	0.00088	0.00411	CcSEcCtD
Azelastine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000876	0.00409	CcSEcCtD
Azelastine—Visual impairment—Carmustine—lymphatic system cancer	0.000869	0.00406	CcSEcCtD
Azelastine—Fatigue—Fludarabine—lymphatic system cancer	0.000863	0.00403	CcSEcCtD
Azelastine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000857	0.004	CcSEcCtD
Azelastine—Constipation—Fludarabine—lymphatic system cancer	0.000856	0.004	CcSEcCtD
Azelastine—Pain—Fludarabine—lymphatic system cancer	0.000856	0.004	CcSEcCtD
Azelastine—Eye disorder—Carmustine—lymphatic system cancer	0.000843	0.00394	CcSEcCtD
Azelastine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000841	0.00392	CcSEcCtD
Azelastine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000839	0.00392	CcSEcCtD
Azelastine—Flushing—Carmustine—lymphatic system cancer	0.000837	0.00391	CcSEcCtD
Azelastine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000835	0.0039	CcSEcCtD
Azelastine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000832	0.00389	CcSEcCtD
Azelastine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000825	0.00385	CcSEcCtD
Azelastine—Asthenia—Teniposide—lymphatic system cancer	0.000817	0.00382	CcSEcCtD
Azelastine—Malaise—Bleomycin—lymphatic system cancer	0.000811	0.00379	CcSEcCtD
Azelastine—Pruritus—Teniposide—lymphatic system cancer	0.000806	0.00376	CcSEcCtD
Azelastine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000792	0.0037	CcSEcCtD
Azelastine—Cough—Bleomycin—lymphatic system cancer	0.000785	0.00366	CcSEcCtD
Azelastine—Diarrhoea—Teniposide—lymphatic system cancer	0.00078	0.00364	CcSEcCtD
Azelastine—Myalgia—Bleomycin—lymphatic system cancer	0.000766	0.00358	CcSEcCtD
Azelastine—Chest pain—Bleomycin—lymphatic system cancer	0.000766	0.00358	CcSEcCtD
Azelastine—Back pain—Carmustine—lymphatic system cancer	0.00076	0.00355	CcSEcCtD
Azelastine—Discomfort—Bleomycin—lymphatic system cancer	0.000757	0.00353	CcSEcCtD
Azelastine—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000752	0.00351	CcSEcCtD
Azelastine—Confusional state—Bleomycin—lymphatic system cancer	0.00074	0.00346	CcSEcCtD
Azelastine—Vision blurred—Carmustine—lymphatic system cancer	0.00074	0.00345	CcSEcCtD
Azelastine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000738	0.00344	CcSEcCtD
Azelastine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000734	0.00343	CcSEcCtD
Azelastine—Infection—Bleomycin—lymphatic system cancer	0.000729	0.00341	CcSEcCtD
Azelastine—Back pain—Vincristine—lymphatic system cancer	0.000725	0.00338	CcSEcCtD
Azelastine—Vomiting—Teniposide—lymphatic system cancer	0.000724	0.00338	CcSEcCtD
Azelastine—Agitation—Carmustine—lymphatic system cancer	0.000722	0.00337	CcSEcCtD
Azelastine—Asthenia—Fludarabine—lymphatic system cancer	0.000718	0.00335	CcSEcCtD
Azelastine—Rash—Teniposide—lymphatic system cancer	0.000718	0.00335	CcSEcCtD
Azelastine—Dermatitis—Teniposide—lymphatic system cancer	0.000718	0.00335	CcSEcCtD
Azelastine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000715	0.00334	CcSEcCtD
Azelastine—Headache—Teniposide—lymphatic system cancer	0.000714	0.00333	CcSEcCtD
Azelastine—Pruritus—Fludarabine—lymphatic system cancer	0.000708	0.00331	CcSEcCtD
Azelastine—Back pain—Mitoxantrone—lymphatic system cancer	0.000706	0.0033	CcSEcCtD
Azelastine—Agitation—Vincristine—lymphatic system cancer	0.000689	0.00322	CcSEcCtD
Azelastine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000688	0.00321	CcSEcCtD
Azelastine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000685	0.0032	CcSEcCtD
Azelastine—Hypertension—Carmustine—lymphatic system cancer	0.000678	0.00316	CcSEcCtD
Azelastine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000677	0.00316	CcSEcCtD
Azelastine—Nausea—Teniposide—lymphatic system cancer	0.000677	0.00316	CcSEcCtD
Azelastine—Vertigo—Vincristine—lymphatic system cancer	0.000673	0.00314	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000669	0.00312	CcSEcCtD
Azelastine—Chest pain—Carmustine—lymphatic system cancer	0.000668	0.00312	CcSEcCtD
Azelastine—Myalgia—Carmustine—lymphatic system cancer	0.000668	0.00312	CcSEcCtD
Azelastine—Anxiety—Carmustine—lymphatic system cancer	0.000666	0.00311	CcSEcCtD
Azelastine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000659	0.00308	CcSEcCtD
Azelastine—Malaise—Mitoxantrone—lymphatic system cancer	0.000658	0.00307	CcSEcCtD
Azelastine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000655	0.00306	CcSEcCtD
Azelastine—Hypertension—Vincristine—lymphatic system cancer	0.000647	0.00302	CcSEcCtD
Azelastine—Confusional state—Carmustine—lymphatic system cancer	0.000646	0.00302	CcSEcCtD
Azelastine—Myalgia—Vincristine—lymphatic system cancer	0.000638	0.00298	CcSEcCtD
Azelastine—Cough—Mitoxantrone—lymphatic system cancer	0.000637	0.00297	CcSEcCtD
Azelastine—Infection—Carmustine—lymphatic system cancer	0.000637	0.00297	CcSEcCtD
Azelastine—Vomiting—Fludarabine—lymphatic system cancer	0.000637	0.00297	CcSEcCtD
Azelastine—Rash—Fludarabine—lymphatic system cancer	0.000631	0.00295	CcSEcCtD
Azelastine—Dermatitis—Fludarabine—lymphatic system cancer	0.000631	0.00294	CcSEcCtD
Azelastine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00063	0.00294	CcSEcCtD
Azelastine—Pain—Bleomycin—lymphatic system cancer	0.000628	0.00293	CcSEcCtD
Azelastine—Headache—Fludarabine—lymphatic system cancer	0.000627	0.00293	CcSEcCtD
Azelastine—Tachycardia—Carmustine—lymphatic system cancer	0.000625	0.00292	CcSEcCtD
Azelastine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000624	0.00291	CcSEcCtD
Azelastine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000621	0.0029	CcSEcCtD
Azelastine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000621	0.0029	CcSEcCtD
Azelastine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000619	0.00289	CcSEcCtD
Azelastine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000614	0.00287	CcSEcCtD
Azelastine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000612	0.00286	CcSEcCtD
Azelastine—Infection—Vincristine—lymphatic system cancer	0.000608	0.00284	CcSEcCtD
Azelastine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000605	0.00282	CcSEcCtD
Azelastine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000601	0.0028	CcSEcCtD
Azelastine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000596	0.00278	CcSEcCtD
Azelastine—Nausea—Fludarabine—lymphatic system cancer	0.000595	0.00278	CcSEcCtD
Azelastine—Infection—Mitoxantrone—lymphatic system cancer	0.000592	0.00276	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000584	0.00273	CcSEcCtD
Azelastine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000581	0.00271	CcSEcCtD
Azelastine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00058	0.00271	CcSEcCtD
Azelastine—Paraesthesia—Carmustine—lymphatic system cancer	0.000575	0.00269	CcSEcCtD
Azelastine—Dyspnoea—Carmustine—lymphatic system cancer	0.000571	0.00267	CcSEcCtD
Azelastine—Somnolence—Carmustine—lymphatic system cancer	0.00057	0.00266	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000557	0.0026	CcSEcCtD
Azelastine—Paraesthesia—Vincristine—lymphatic system cancer	0.000549	0.00256	CcSEcCtD
Azelastine—Constipation—Carmustine—lymphatic system cancer	0.000548	0.00256	CcSEcCtD
Azelastine—Pain—Carmustine—lymphatic system cancer	0.000548	0.00256	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000543	0.00253	CcSEcCtD
Azelastine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000541	0.00253	CcSEcCtD
Azelastine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000535	0.0025	CcSEcCtD
Azelastine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000531	0.00248	CcSEcCtD
Azelastine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00053	0.00247	CcSEcCtD
Azelastine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000528	0.00247	CcSEcCtD
Azelastine—Fatigue—Vincristine—lymphatic system cancer	0.000527	0.00246	CcSEcCtD
Azelastine—Asthenia—Bleomycin—lymphatic system cancer	0.000527	0.00246	CcSEcCtD
Azelastine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000524	0.00245	CcSEcCtD
Azelastine—Constipation—Vincristine—lymphatic system cancer	0.000523	0.00244	CcSEcCtD
Azelastine—Pain—Vincristine—lymphatic system cancer	0.000523	0.00244	CcSEcCtD
Azelastine—Asthma—Methotrexate—lymphatic system cancer	0.000522	0.00244	CcSEcCtD
Azelastine—Pruritus—Bleomycin—lymphatic system cancer	0.000519	0.00242	CcSEcCtD
Azelastine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000514	0.0024	CcSEcCtD
Azelastine—Pain—Mitoxantrone—lymphatic system cancer	0.000509	0.00238	CcSEcCtD
Azelastine—Constipation—Mitoxantrone—lymphatic system cancer	0.000509	0.00238	CcSEcCtD
Azelastine—Abdominal pain—Carmustine—lymphatic system cancer	0.000507	0.00237	CcSEcCtD
Azelastine—Body temperature increased—Carmustine—lymphatic system cancer	0.000507	0.00237	CcSEcCtD
Azelastine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0005	0.00234	CcSEcCtD
Azelastine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000491	0.00229	CcSEcCtD
Azelastine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000487	0.00227	CcSEcCtD
Azelastine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000485	0.00226	CcSEcCtD
Azelastine—Body temperature increased—Vincristine—lymphatic system cancer	0.000484	0.00226	CcSEcCtD
Azelastine—Abdominal pain—Vincristine—lymphatic system cancer	0.000484	0.00226	CcSEcCtD
Azelastine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000472	0.0022	CcSEcCtD
Azelastine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000471	0.0022	CcSEcCtD
Azelastine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000471	0.0022	CcSEcCtD
Azelastine—Vomiting—Bleomycin—lymphatic system cancer	0.000467	0.00218	CcSEcCtD
Azelastine—Rash—Bleomycin—lymphatic system cancer	0.000463	0.00216	CcSEcCtD
Azelastine—Dermatitis—Bleomycin—lymphatic system cancer	0.000462	0.00216	CcSEcCtD
Azelastine—Asthenia—Carmustine—lymphatic system cancer	0.00046	0.00215	CcSEcCtD
Azelastine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000452	0.00211	CcSEcCtD
Azelastine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000451	0.0021	CcSEcCtD
Azelastine—Haematuria—Methotrexate—lymphatic system cancer	0.000444	0.00207	CcSEcCtD
Azelastine—Epistaxis—Methotrexate—lymphatic system cancer	0.000439	0.00205	CcSEcCtD
Azelastine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000439	0.00205	CcSEcCtD
Azelastine—Asthenia—Vincristine—lymphatic system cancer	0.000439	0.00205	CcSEcCtD
Azelastine—Diarrhoea—Carmustine—lymphatic system cancer	0.000438	0.00205	CcSEcCtD
Azelastine—Nausea—Bleomycin—lymphatic system cancer	0.000436	0.00204	CcSEcCtD
Azelastine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000427	0.002	CcSEcCtD
Azelastine—Dizziness—Carmustine—lymphatic system cancer	0.000424	0.00198	CcSEcCtD
Azelastine—Diarrhoea—Vincristine—lymphatic system cancer	0.000419	0.00195	CcSEcCtD
Azelastine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000415	0.00194	CcSEcCtD
Azelastine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000408	0.0019	CcSEcCtD
Azelastine—Vomiting—Carmustine—lymphatic system cancer	0.000407	0.0019	CcSEcCtD
Azelastine—Dizziness—Vincristine—lymphatic system cancer	0.000405	0.00189	CcSEcCtD
Azelastine—Rash—Carmustine—lymphatic system cancer	0.000404	0.00189	CcSEcCtD
Azelastine—Dermatitis—Carmustine—lymphatic system cancer	0.000404	0.00188	CcSEcCtD
Azelastine—Visual impairment—Methotrexate—lymphatic system cancer	0.000403	0.00188	CcSEcCtD
Azelastine—Headache—Carmustine—lymphatic system cancer	0.000401	0.00187	CcSEcCtD
Azelastine—Eye disorder—Methotrexate—lymphatic system cancer	0.00039	0.00182	CcSEcCtD
Azelastine—Vomiting—Vincristine—lymphatic system cancer	0.000389	0.00182	CcSEcCtD
Azelastine—Rash—Vincristine—lymphatic system cancer	0.000386	0.0018	CcSEcCtD
Azelastine—Dermatitis—Vincristine—lymphatic system cancer	0.000385	0.0018	CcSEcCtD
Azelastine—Headache—Vincristine—lymphatic system cancer	0.000383	0.00179	CcSEcCtD
Azelastine—Nausea—Carmustine—lymphatic system cancer	0.000381	0.00178	CcSEcCtD
Azelastine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000379	0.00177	CcSEcCtD
Azelastine—Rash—Mitoxantrone—lymphatic system cancer	0.000376	0.00175	CcSEcCtD
Azelastine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000375	0.00175	CcSEcCtD
Azelastine—Headache—Mitoxantrone—lymphatic system cancer	0.000373	0.00174	CcSEcCtD
Azelastine—Nausea—Vincristine—lymphatic system cancer	0.000363	0.0017	CcSEcCtD
Azelastine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000356	0.00166	CcSEcCtD
Azelastine—Nausea—Mitoxantrone—lymphatic system cancer	0.000354	0.00165	CcSEcCtD
Azelastine—Back pain—Methotrexate—lymphatic system cancer	0.000352	0.00164	CcSEcCtD
Azelastine—Vision blurred—Methotrexate—lymphatic system cancer	0.000343	0.0016	CcSEcCtD
Azelastine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000337	0.00158	CcSEcCtD
Azelastine—Malaise—Methotrexate—lymphatic system cancer	0.000328	0.00153	CcSEcCtD
Azelastine—Vertigo—Methotrexate—lymphatic system cancer	0.000327	0.00153	CcSEcCtD
Azelastine—Cough—Methotrexate—lymphatic system cancer	0.000317	0.00148	CcSEcCtD
Azelastine—Myalgia—Methotrexate—lymphatic system cancer	0.00031	0.00145	CcSEcCtD
Azelastine—Chest pain—Methotrexate—lymphatic system cancer	0.00031	0.00145	CcSEcCtD
Azelastine—Discomfort—Methotrexate—lymphatic system cancer	0.000306	0.00143	CcSEcCtD
Azelastine—Confusional state—Methotrexate—lymphatic system cancer	0.000299	0.0014	CcSEcCtD
Azelastine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000297	0.00139	CcSEcCtD
Azelastine—Infection—Methotrexate—lymphatic system cancer	0.000295	0.00138	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00027	0.00126	CcSEcCtD
Azelastine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000267	0.00124	CcSEcCtD
Azelastine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000265	0.00124	CcSEcCtD
Azelastine—Somnolence—Methotrexate—lymphatic system cancer	0.000264	0.00123	CcSEcCtD
Azelastine—Fatigue—Methotrexate—lymphatic system cancer	0.000256	0.00119	CcSEcCtD
Azelastine—Pain—Methotrexate—lymphatic system cancer	0.000254	0.00119	CcSEcCtD
Azelastine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000245	0.00114	CcSEcCtD
Azelastine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000243	0.00113	CcSEcCtD
Azelastine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000235	0.0011	CcSEcCtD
Azelastine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000235	0.0011	CcSEcCtD
Azelastine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000219	0.00102	CcSEcCtD
Azelastine—Asthenia—Methotrexate—lymphatic system cancer	0.000213	0.000994	CcSEcCtD
Azelastine—Pruritus—Methotrexate—lymphatic system cancer	0.00021	0.00098	CcSEcCtD
Azelastine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000203	0.000948	CcSEcCtD
Azelastine—Dizziness—Methotrexate—lymphatic system cancer	0.000196	0.000916	CcSEcCtD
Azelastine—Vomiting—Methotrexate—lymphatic system cancer	0.000189	0.000881	CcSEcCtD
Azelastine—Rash—Methotrexate—lymphatic system cancer	0.000187	0.000874	CcSEcCtD
Azelastine—Dermatitis—Methotrexate—lymphatic system cancer	0.000187	0.000873	CcSEcCtD
Azelastine—Headache—Methotrexate—lymphatic system cancer	0.000186	0.000868	CcSEcCtD
Azelastine—Nausea—Methotrexate—lymphatic system cancer	0.000176	0.000823	CcSEcCtD
